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Abstract 
Background: Smith–Magenis syndrome (SMS) is a rare genetic neurodevelopmental disorder characterized by 
intellectual disability and severe behavioural and sleep disturbances. Often, patients with SMS are diagnosed with 
attention‑deficit/hyperactivity disorder (ADHD). However, the effectiveness of methylphenidate (MPH), the first‑line 
pharmacological treatment for ADHD, in patients with SMS is unclear. Our objective is to examine the effectiveness 
of MPH for ADHD symptoms in individuals with SMS, proposing an alternative trial design as traditional randomized 
controlled trials are complex in these rare and heterogeneous patient populations.
Methods and analysis: We will initiate an N‑of‑1 series of double‑blind randomized and placebo‑controlled multiple 
crossover trials in six patients aged ≥ 6 years with a genetically confirmed SMS diagnosis and a multidisciplinary estab‑
lished ADHD diagnosis, according to a power analysis based on a summary measures analysis of the treatment effect. 
Each N‑of‑1 trial consists of a baseline period, dose titration phase, three cycles each including randomized interven‑
tion, placebo and washout periods, and follow‑up. The intervention includes twice daily MPH (doses based on age 
and body weight). The primary outcome measure will be the subscale hyperactivity/inattention of the Strengths and 
Difficulties Questionnaire (SDQ), rated daily. Secondary outcome measures are the shortened version of the Emo‑
tion Dysregulation Inventory (EDI) reactivity index, Goal Attainment Scaling (GAS), and the personal questionnaire 
(PQ). Statistical analysis will include a mixed model analysis. All subjects will receive an assessment of their individual 
treatment effect and data will be aggregated to investigate the effectiveness of MPH for ADHD in SMS at a population 
level.
Conclusions: This study will provide information on the effectiveness of MPH for ADHD in SMS, incorporating 
personalized outcome measures. This protocol presents the first properly powered N‑of‑1 study in a rare genetic 
neurodevelopmental disorder, providing a much‑needed bridge between science and practice to optimize evidence‑
based and personalized care.
Trial registration : This study is registered in the Netherlands Trial Register (NTR9125).
Keywords: N‑of‑1, Smith–Magenis syndrome, Methylphenidate, Rare genetic neurodevelopmental disorder, Multiple 
crossover, ADHD
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Highlights of the study protocol
• Innovative trial design combining collection of scien-
tific data with personalized care, providing a much-
needed bridge between practice and science.
• Evidence-based treatment of ADHD symptoms in 
Smith–Magenis syndrome.
• The first adequately powered series of randomized, 
double-blind, placebo-controlled N-of-1 trials for a 
rare genetic neurodevelopmental disorder.
• Exploring patient-centered outcome measures 
addressing relevant goals of the patient.
Background
Smith–Magenis syndrome (SMS) is a rare genetic neu-
rodevelopmental disorder with an estimated prevalence 
of 1:15.000–25.000 births [1]. SMS is caused by a deletion 
on chromosome 17 (17p11.2) or a pathogenic mutation 
in the RAI1 gene located within this region. Most of the 
SMS manifestations are due to haploinsufficiency of RAI1 
and thought to be modified by other genes in the 17p11.2 
region [2–4]. Manifestations are variable and include 
intellectual disability (ID), severe sleep disturbances 
and psychiatric comorbidity such as autism spectrum 
disorders (ASD), attention-deficit-hyperactivity disor-
der (ADHD) [5–7]. Typical behavioural manifestations 
include problems with emotion dysregulation, self-injuri-
ous behaviour and aggressive or stereotypical behaviour, 
posing a great burden on patients and caregivers [8].
Treatment of the behavioural manifestations in SMS is 
complex due to the genetic heterogeneity, clinical varia-
bility and severity of symptoms [4, 9]. Traditionally, treat-
ment is focused on appropriate management of sleeping 
pattern, concomitant somatic comorbidities, psycho-
education and professional guidance for parents and 
caregivers aimed at symptom reduction and optimizing 
quality of life of both the patient and their family [10–13]. 
Often, this does not suffice, resulting in the prescription 
of psychotropic drugs in the vast majority of children and 
adults with SMS, including stimulants, antidepressants, 
antipsychotics, mood stabilizers, alfa2 agonists, sleep 
aids, and benzodiazepines [14].
For idiopathic ADHD, methylphenidate (MPH) is well-
established as first-line treatment with high efficacy and 
tolerability compared to other psychotropic drugs [15–
17]. However, for ADHD in genetic neurodevelopmen-
tal disorders such as SMS more information is necessary 
as there is increasing evidence for differential treatment 
response and tolerability [14, 18, 19]. Also, polypharmacy 
is a clinical pitfall in patients with complex psychiatric 
disorders and ID, leading to iatrogenic comorbidity [20]. 
Therefore, disorder-specific studies are needed to provide 
information about the effectiveness of MPH for ADHD. 
Considering the heterogeneity of the patient population 
and need for relevancy of interventions, personalized 
outcome measures are needed to enable measurement of 
clinically important changes. Such a personalized meth-
odological approach has the potential of maximizing 
treatment adherence that is both patient-centered and 
evidence-based [21–23].
Rationale for N‑of‑1 design
Trials in rare genetic neurodevelopmental disorders such 
as SMS pose specific challenges due to comorbidities 
and rarity of conditions [24, 25]. Single-case experimen-
tal designs (SCEDs) provide an alternative to traditional 
parallel group randomized controlled trials (RCTs). Of 
SCEDs, the N-of-1 methodology provides the most rigor-
ous evidence for treatment decisions at an individual level 
as replication is key for confirmation of causality. N-of-1 
studies are randomized, controlled, multiple cross-over 
trials within individual patients [26, 27] and enhance pre-
cision when treatment effects are heterogeneous between 
individuals [28, 29]. Aggregating the results of several 
N-of-1 trials potentially yields treatment effect estimates 
that may be generalized at population level and may be 
as robust as traditional RCTs [30]. In particular, patients 
with rare disorders require individualized treatment 
interventions and outcomes due to their heterogeneity 
and vulnerability, which is facilitated by N-of-1 designs 
and consistent with the movement towards personalized 
care, providing a much needed bridge between practice 
and science [21].
Objectives
The main objective is to study the effectiveness of MPH 
for ADHD symptoms in individuals with SMS. Second-
ary objectives include assessment of the effect of MPH on 
emotion dysregulation, personalized goals that are spe-
cific and important to the patient, and side effects. To do 
this, we will perform a series of N-of-1 trials as these pro-
vide an excellent approach to study effectiveness of MPH 
on ADHD in SMS, given: (1) the chronic and relatively 
stable clinical course of ADHD, and (2) the rapid onset 
and termination of action of MPH [31].
Methods
Study design
We used the Standard Protocol Items: Recommendations 
for Interventional Trials (SPIRIT) extension for N-of-1 
trials (SPENT) checklist that is aligned with the CON-
SORT (consolidated reporting items for trials) extension 
for N-of-1 trials (CENT) for developing this N-of-1 pro-
tocol [29].
Page 3 of 9Müller et al. Orphanet J Rare Dis          (2021) 16:380  
The study will consist of a series of N-of-1 trials fol-
lowed by an optional open-label extension phase. Each 
trial is randomized, placebo-controlled, and double-
blinded with multiple crossovers within a single patient. 
The trial consists of a baseline period, dose titration 
phase, and three cycles each consisting of one period of 
MPH treatment and one period of placebo treatment, 
both followed by a one-week washout period (Fig.  1). 
Despite the fact that a one-day washout would suffice 
biologically, we chose one-week washouts to account 
for prolonged psychological effects that may occur. The 
order of the treatment periods will be randomized. Thus, 
each N-of-1 trial will last 14 weeks with an additional fol-
low-up measurement three months after completion of 
the N-of-1 trial.
Protocol development and patient engagement
Collaboration with the Dutch SMS patient advocacy 
organization, caregivers of patients and clinical experts 
played a large role in defining knowledge and care gaps, 
prioritizing the treatment study, development of the 
current protocol and selecting outcome measures. We 
addressed specific difficulties for conducting this study, 
including concerns related to caregiver burden and 
patient burden of participation, and issues for recruit-
ment and retention.
Outcome measures
The primary outcome is the change on the hyperactiv-
ity/inattention subscale of the Strengths and Difficulties 
Questionnaire (SDQ) during active interventional peri-
ods. Secondary outcome measures are the shortened 
version of the Emotion Dysregulation Inventory (EDI) 
reactivity index [32], Goal Attainment Scaling (GAS) 
[33] and the personal questionnaire (PQ) [34]. Also, (the 
number of ) side effects determined by the side effects 
checklist of MPH will be recorded.
Rationale for outcome measures
The SDQ subscale and the shortened version of the EDI 
have both been psychometrically considered as valid 
tools to measure behavior of people with ID and appli-
cable to both children and adults [32, 35, 36]. Specifi-
cally, the SDQ was found to be a valid outcome measure 
for children with ADHD symptoms and showed pre-
liminary results of validation for children with ID [37, 
38]. EDI was created using methods developed by the 
Patient-Reported Outcomes Measurement Information 
System (PROMIS) and validated as an efficient and sensi-
tive method to measure emotion dysregulation in youth 
with ASD of any level of cognitive or verbal ability [32, 
36]. The EDI will serve as a generalization measure that 
is defined as an outcome closely or more distally related 
to the target behavior, and is used to evaluate transfer 
effects of the intervention to a broader domain of func-
tioning [39]. For instance, it could be the same behavior 
but in another setting, such as inattention at school and 
at home, or interventional effects on a completely dif-
ferent behavior, such as improved emotion regulation 
when the target behavior is impulsivity. In addition to 
the target behaviors hyperactivity and inattention in our 
study, measured by the SDQ, MPH might affect emotion 
dysregulation as well, which could be measured by the 
EDI. GAS is an individualized outcome measure involv-
ing goal selection and goal scaling that is standardized 
in order to calculate the extent to which a patient’s goals 
are met. Patients and/or their caregivers are allowed to 
choose their own specific goals in coordination with their 
treating physician/therapist. This makes GAS a measure-
ment instrument that is very sensitive to change, particu-
larly in small heterogeneous groups.
As the population with ID often presents with atypi-
cal side effects, a standardized checklist of side effects 
of MPH [40] together with an open interview to capture 
possible atypical side effects will be used to determine 
(the number of ) side effects including sleeping problems.
Study population
The study population consists of children or adults from 
the Netherlands with SMS and an ADHD diagnosis 
established by a multidisciplinary team. Inclusion criteria 






























Fig. 1 Study design
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diagnosis of SMS, and the availability of a caregiver for 
proxy-reports. Baseline characteristics will be recorded 
in detail, including age, gender, genetic test results, 
comorbidity, and medication. Exclusion criteria include 
presence of a contra-indication for MPH, planned general 
anesthesia, pregnancy, breastfeeding, current treatment 
with biologically interfering drugs, substance or alcohol 
abuse, and incapacity to swallow tablets. The latter may 
however bias the sample toward a higher functioning 
segment of SMS. We aim to conduct a patient-centered 
trial, allowing for a natural setting and flexibility, includ-
ing the continuation of concurrent therapies such as (for 
example) sleep medication. Use of concurrent therapies 
will be recorded.
Sample size
The sample size calculation was based on a summary 
measures analysis of the treatment effect as measured 
with the primary outcome SDQ [41]. The difference 
between the mean SDQ hyperactivity/inattention rat-
ings in MPH periods and placebo periods was used as 
a summary measure for the treatment effect in an indi-
vidual subject. The estimated standard deviation (SD) of 
2.3 points for single ratings was used based on a reported 
standard error for the parent-rated SDQ subscale [42]. 
Using a test–retest intraclass correlation coefficient (ICC) 
of 0.84 [43], we decomposed a SD into a within-subject 
SD of 0.92 and a between-subject SD of 2.11. Assuming 
an SD of 1 point for the treatment effect, 95% of the sub-
ject-specific treatment effects roughly falls within a range 
of 4 points. Based on the estimate assuming three cycles 
with seven daily SDQ ratings within each period, a total 
of 6 subjects will yield 80% power to detect a mean differ-
ence of 1.5 points between intervention and placebo peri-
ods when assuming a two-sided significance level of 5%.
Recruitment
Study subjects will be recruited through the two national 
Dutch SMS multidisciplinary outpatient clinics of ‘s 
Heeren Loo, and the Dutch SMS patient advocacy 
organization.
Trial procedure and study setting
Prior to the start of the trials, the participant and substi-
tute decision maker(s) will have a clinical visit to discuss 
the procedure in detail and sign the informed consent. 
Personalized goals with regard to GAS and the PQ and 
target symptoms will be identified together by the par-
ents and/or primary caregivers, the treating physician, 
psychologist and/or behavioural therapist, and investi-
gator. During the clinical visit, it will be emphasized that 
assessors should rate the global effect over the day and 
should be aware of the possible rebound effect of MPH. 
The study will be carried out at participants’ home set-
ting and schools or daytime centres if applicable.
The trial will start with a baseline period of seven days 
without any intervention. A dose titration phase of six 
days is followed by a washout period of eight days. The 
individual N-of-1 trial will consist of three cycles each 
containing four seven-day periods: one active treatment 
(A), one placebo treatment (B), and two ‘washout’ periods 
following A and B. The order in which patients receive 
active and placebo treatment is randomized within each 
cycle. The medication will be administered at home and/
or at school or daytime activities by parents or primary 
caregivers. During the baseline period and three cycles, 
the SDQ and EDI will be filled out daily at the end of the 
day using app-based questionnaires by primary caregiv-
ers (Fig. 2). Filling out the questionnaires will take about 1 
min a day. At the end of each seven-day period, the inves-
tigator will interview patients and/or primary caregivers 
by phone to evaluate goals [33], to assess possible side 
Fig. 2 Time schedule of enrolment, interventions, and assessments. Underlined crosses (X) indicate assessments via phone calls. Asterisks (*) 
indicate the moment with a clinical visit. EDI Emotion Dysregulation Inventory, GAS Goal Attainment Scaling, PQ personal questionnaire, SDQ 
Strengths and Difficulties Questionnaire
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effects, to note the general moments that the interven-
tional effects seem to wear off, and to note the perceived 
treatment received (MPH or placebo). The time expected 
to complete this interview is 15  min. Each period will 
include a weekend such that parents can provide assess-
ments of complete days. At the end of the trial period, 
the participant will have a second and final clinical visit 
to evaluate the symptoms and study. In consultation with 
the treating physician, patients may continue with MPH 
treatment, whether or not at a different dosage. Three 
months after terminating the N-of-1 trial, another con-
tact moment will take place for a follow-up measurement 
in which the questionnaires will be filled out and the 
goals and items of GAS and PQ will be discussed again. 
To reduce burden as much as possible, assessments solely 
occur by phone calls apart from the two study visits. The 
total duration of the trial will be 14 weeks with the addi-
tional follow-up measurement after three months.
Blinding, treatment allocation, randomization
Participants, parents, caregivers, supervisors of daily 
activities, clinicians and researchers will all be blinded 
during the N-of-1 trial. The random allocation sequence 
will be generated and implemented by the hospital phar-
macist for block randomization in a 1:1 ratio and sequen-
tially numbered packages. Participants and the treating 
physician will be deblinded after completing the three 
cycles or in case of serious adverse events (SAEs). Investi-
gators involved in data analysis will remain blinded until 
the end of the follow-up period.
Multi‑site training plan
A pre-study training meeting will be planned to train 
clinical investigators and clinical evaluators on study 
procedures and GAS with a secondary goal to promote 
reliability of GAS. All clinical and research staff that is 
involved in either identification or assessment of goals 
by GAS will be trained by a GAS expert to promote data 
quality.
Interventions and dosing schedule
One dose titration kit and a trial kit including MPH (reg-
ular tablet) and placebo will be developed and distributed 
by the Amsterdam UMC hospital pharmacist.
Dose titration phase
The MPH dosage will be titrated to achieve the maximum 
dosage with minimal side effects determined by the psy-
chiatrist or ID physician. Titration dosage will be blinded 
to the participants and caregivers and comprise two days 
each of three escalating doses in steps of 2.5 mg of MPH 
with a total of six days followed by a washout period of at 
least one week. The individually determined starting dose 
for the dose titration phase will be based on age and body 
weight. During the dose titration phase, participants will 
daily fill out the checklist of side effects of MPH [40]. 
MPH effectiveness will explicitly not be examined during 
the titration phase to prevent high dropout rates when 
participants might get prematurely convinced about the 
effectiveness.
Trial
During the N-of-1 trial, MPH dosage as determined by 
titration phase or placebo will be administered by car-
egivers twice daily during breakfast and during lunch 
(around 7.30 am and 12.30 pm). During washout periods, 
the placebo will be administered.
Follow‑up
After the final cycle and unblinding, the participant’s sub-
stitute decision maker(s) and clinician will decide on fur-
ther continuation of MPH treatment before the follow-up 
measurement. Although a dose titration phase precedes 
the trial to have a fixed dosage during the N-of-1 trial, 
participants can switch from dosage or discontinue with 
MPH in consultation with the treating physician in the 
follow-up period.
Safety evaluation
Subjects can leave the study at any time for any rea-
son. The investigator may decide to withdraw a subject 
from the study for urgent medical reasons. Reasons may 
include occurrence of treatment-related SAEs or sus-
pected unexpected serious adverse reaction (SUSAR), 
deterioration of symptoms that require a treatment other 
than the medication of the trial, and a sudden and acute 
medical condition related or unrelated to SMS that may 
interfere with the study. Any sign that indicates resist-
ance among children and mentally incompetent partici-
pants, which is defined and discussed with parents and 
caregivers in advance, will lead to discontinuation of the 
trial. Completed cycles before withdrawal of a participant 
will still be analysed. In case of drop-out, a new partici-
pant that meets the inclusion criteria will be recruited 
with a newly randomized sequence. The sponsor will sus-
pend the study if there is sufficient ground that continu-
ation of the study will jeopardise subject health or safety.
Monitoring will be conducted by independent qualified 
monitors from the Clinical Monitoring Center (CMC). 
All adverse events (AEs) will be monitored and followed 
until they have abated, or until a stable situation has been 
reached. Depending on the event, follow-up may require 
additional tests or medical procedures as indicated, 
and/or referral to the general practitioner or a medical 
specialist.
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Data collection and management
All data will be collected and handled in accordance with 
the EU General Data Protection Regulation, the Dutch 
Act on Implementation of the General Data Protec-
tion Regulation and Amsterdam UMC standard operat-
ing procedures. The Case Report Forms (CRFs) and trial 
specific documents held by the researcher will be stored 
securely with access restricted and limited to nominated 
research staff recorded on the delegation log. A data shar-
ing agreement between Amsterdam UMC and ‘s Heeren 
Loo will manage additional access for investigators.
The CRFs will be set up in Castor Electronic Data Cap-
ture (EDC) in which weekly assessments will be entered. 
Questionnaires can be filled out digitally using the 
m-Path app on smartphones [44], on computers (Castor 
EDC) or by using paper forms. Data from the app will be 
collected at the end of each trial and will be loaded into 
Castor EDC. In advance, participants will be recom-
mended to download the m-Path app to easily and con-
fidentially answer the daily questionnaires, although the 
use of different ways is allowed to enlarge feasibility for 
raters. For the sake of participant retention, automatic 
reminders will be sent to raters when questionnaires 
have not yet been filled in. Participant burden will be lim-
ited as much as possible by having contact moments by 
video-conference or phone instead of a visit. The inves-
tigator can also decide to withdraw a subject for urgent 
medical reasons. A participant who withdraws consent 
for an assessment of one outcome may be willing to con-
tinue with assessments for other outcomes.
A subject identification code list will be used with 
unique participant identifiers not deducible to patients. 
Only two investigators will have access to the key. In 
addition, two methodologists and biostatisticians will 
have access to the source data for methodological and 
statistical purposes. Data will be stored for 15  years 
according to the Amsterdam UMC regulations.
Statistical methods
An individual treatment effect for each participant will be 
determined based on summary statistics. A mixed model 
analysis will be applied for analysing the effectiveness of 
the intervention at the population level combining data 
from the individual N-of-1 trials.
The mean treatment effect on the primary outcome 
will be estimated and tested for significance using a lin-
ear mixed model with a fixed effect for treatment (MPH 
or placebo) and random effects for patient, cycle within 
patient, and treatment (within patient). The mixed model 
will account for between-subjects heterogeneity in treat-
ment effect through inclusion of the random treatment 
effect. Small amounts of missing data will not pose prob-
lems for the mixed model analysis because of the many 
data points per period, assuming data is missing at ran-
dom. If issues such as singularity arise due to complexity 
of the models, an analysis based on a summary measure 
will be performed. A similar method will be used for esti-
mating treatment effects on secondary study parameters. 
A two-sided significance level of 5% will be used. Analy-
ses will be performed in R, using the lmer package.
Discussion
To date, research on the efficacy of treatment strategies 
for behavioural aspects of SMS has been limited. In this 
N-of-1 series of randomized, placebo-controlled, double-
blind multiple crossover trials in patients with SMS and 
ADHD, the effectiveness of MPH for ADHD symptoms 
will be examined, including personalized goals as addi-
tional outcomes.
N-of-1 studies provide a powerful alternative to larger 
RCTs, but are still only sporadically reported in rare 
genetic neurodevelopmental disorders [45]. Debate is 
still ongoing to what extent an N-of-1 study represents 
medical research or is part of evidence-based clinical 
care [46–48]. For instance, for some practitioners start-
ing MPH treatment, blinded crossover periods, the use 
of placebo and filling out questionnaires is already part 
of standard care. To provide evidence-based treatment 
decisions and to prevent polypharmacy, N-of-1 studies 
might be considered as a much-needed part of clinical 
care especially in complex patient populations such as 
individuals with SMs.
Combining personalized and relevant treatment targets 
while pursuing optimal generalizability is challenging in 
heterogeneous patient populations such as SMs. Because 
SMs is accompanied by various and often variable levels 
of ID and comorbidities, clear diagnostic and eligibility 
criteria are necessary and baseline characteristics, con-
current therapies, comorbid conditions and target symp-
toms will be clearly defined to optimize interpretation 
and generalizability. Also, we will elaborate on setting 
and location as assessments will be in the participant’s 
natural environment.
Regarding this symptomatic pharmacological inter-
vention, we chose to add a baseline period. This period 
allows us to observe the behavior in a non-clinical trial 
setting and to take the natural course of ADHD symp-
toms into account. Moreover, to ensure optimal efficacy, 
tolerability and hence compliance, the highest dosage 
without side effects will be chosen based on the dose 
titration phase.
As for the design, the number of participants and 
crossover periods to detect a clinically relevant treat-
ment effect was selected based on a power analysis, pro-
viding the first properly powered N-of-1 study in a rare 
genetic neurodevelopmental disorder [41]. These are 
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needed when intending to provide estimates of the treat-
ment effect at a population level. Duration of periods was 
based on the pharmacokinetics and -dynamics of MPH. 
Although no washout period would suffice pharmaco-
logically, one-week washouts were chosen to account 
for prolonged psychological effects and for planning 
purposes.
To pursue optimal generalizability to the entire SMS 
population, it is of great importance that outcome meas-
ures are validated for the patient population and sensi-
tive to change. Multiple data points per period will be 
acquired to enable estimation of between and within-
period variances. To increase the study’s validity, each 
interventional period includes at least five measurements 
of the target symptoms, by using the subscale of the SDQ 
[26, 49]. Several other domains of measurement were 
chosen, such as sleep quality and personalized measure-
ments. GAS also allows for capturing goals in reduction 
of caregiver stress, as reduction in symptoms may have 
benefit for family as well. The EDI will also serve as a 
generalization measure to evaluate transfer effects of the 
intervention to a broader domain of functioning. Gener-
alization measures are dependent variables that are taken 
in addition to the target behavior that are used to evalu-
ate whether an intervention generalizes to other behav-
iors or settings [39]. A shortened version and a subscale 
of two outcome measures were selected to minimize 
assessor’s burden.
Personalized outcome measures such as GAS and the 
PQ were chosen to appraise subjective experiences in 
daily life, enabling quantitative expression of meaningful 
subjective patient experiences while translating these into 
evidence [50]. Trials tailored to participants by using per-
sonalized outcomes may improve treatment adherence as 
well. Although GAS has not yet been validated and per-
formed in N-of-1 designs nor as an outcome measure in 
rare genetic disorders with ID, it may be a valuable tool 
in a complex and heterogeneous population such as SMS. 
This study will introduce GAS in the N-of-1 design and 
might be a step towards validation of this personalized 
outcome measure in rare disorders.
Regarding the analysis, a mixed model analysis was 
selected to analyze the effectiveness of the intervention 
at the population level, accounting for between-subjects 
heterogeneity. Ancillary analyses will be performed to 
evaluate period effects and intrasubject correlation.
Limited burden is expected and maximal relevance and 
treatment adherence is ensured, as an N-of-1 study pro-
vides the unique opportunity to tailor interventions and 
outcomes to individual patients. To optimize compliance, 
daily questionnaires will be filled out using a user-friendly 
app and contact moments will mainly take place via digi-
tal or telephone calls. Caregivers may experience some 
burden because of longer withholding of active medica-
tion due to one-week washouts to account for eventual 
psychological effects; this was also the main aberrance 
from clinical care, necessitating institutional review 
board (IRB)-approval. On the other hand, every partici-
pant is exposed to the active treatment condition and the 
effect of the individual treatment will be assessed in the 
best available way, minimizing placebo effects, observer 
effects, and confirmation biases. After the N-of-1 trial, 
participants and their representative(s) will be fully 
informed on the effectiveness of the intervention, allow-
ing shared decision making on future treatment. Partici-
pants might thus be particularly motivated to participate 
in an N-of-1 study due to the existing paucity of evidence 
and the fact that all subjects will receive an evidence-
based assessment of their individual treatment effect.
Conclusion
This N-of-1 study will allow the delivery of personalized 
care while acquiring evidence of MPH for ADHD in the 
SMS population. We expect that use of the N-of-1 meth-
odology and patient-centered outcome measures will 
assist in realizing the urgently needed evidence-based 
interventions in patients with rare genetic neurodevel-
opmental disorders. This protocol will be applicable for 
other genetic syndromes, and more N-of-1 series will 
allow cross-disorder comparisons and investigation of 
generalizability to the whole population with these dis-
orders and/or ID. This study protocol can be used as a 
model to empower other clinician-researchers to inves-
tigate much-needed symptomatic pharmacological as 
well as disease-modifying interventions in rare disorders 
using a collaborative and multi-disciplinary approach.
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